JP2023512025A5 - - Google Patents

Info

Publication number
JP2023512025A5
JP2023512025A5 JP2022546019A JP2022546019A JP2023512025A5 JP 2023512025 A5 JP2023512025 A5 JP 2023512025A5 JP 2022546019 A JP2022546019 A JP 2022546019A JP 2022546019 A JP2022546019 A JP 2022546019A JP 2023512025 A5 JP2023512025 A5 JP 2023512025A5
Authority
JP
Japan
Prior art keywords
rhodatristat
ethyl
compound
item
certain amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512025A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000046 external-priority patent/WO2021152398A1/en
Publication of JP2023512025A publication Critical patent/JP2023512025A/ja
Publication of JP2023512025A5 publication Critical patent/JP2023512025A5/ja
Pending legal-status Critical Current

Links

JP2022546019A 2020-01-31 2021-01-29 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法 Pending JP2023512025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968651P 2020-01-31 2020-01-31
US62/968,651 2020-01-31
PCT/IB2021/000046 WO2021152398A1 (en) 2020-01-31 2021-01-29 Dosages and methods for treating pulmonary arterial hypertension with rodatristat

Publications (2)

Publication Number Publication Date
JP2023512025A JP2023512025A (ja) 2023-03-23
JP2023512025A5 true JP2023512025A5 (enExample) 2024-01-25

Family

ID=75143674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546019A Pending JP2023512025A (ja) 2020-01-31 2021-01-29 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法

Country Status (9)

Country Link
US (1) US20230074252A1 (enExample)
EP (1) EP4096633A1 (enExample)
JP (1) JP2023512025A (enExample)
KR (1) KR20220156813A (enExample)
CN (1) CN115379825A (enExample)
AU (1) AU2021212355A1 (enExample)
CA (1) CA3165432A1 (enExample)
MX (1) MX2022009254A (enExample)
WO (1) WO2021152398A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210105343A (ko) 2018-11-16 2021-08-26 알타반트 사이언시스 게엠베하 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl
WO2023079486A1 (en) * 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제

Similar Documents

Publication Publication Date Title
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2014515373A5 (enExample)
JP2023503309A5 (enExample)
JP2022519385A5 (enExample)
JP2022545835A5 (enExample)
EP1628682B1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor for the treatment of copd
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
JP2010248252A5 (enExample)
JP2009514874A5 (enExample)
JP2006506378A5 (enExample)
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
JP2007532607A5 (enExample)
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2024507810A5 (enExample)
JP2017514911A5 (enExample)
JP2009530295A5 (enExample)
JP2022507533A5 (enExample)
JP2009517411A5 (enExample)
MX2022009254A (es) Dosificacion y metodos para tratar la hipertension arterial pulmonar.
JP2020500868A5 (enExample)
JP2006511538A5 (enExample)
JP2020536098A5 (enExample)
JP2025504219A5 (enExample)
US10052328B2 (en) Therapeutic composition to treat lesions caused by Herpes Simplex Virus